Spectral Diagnostics (EDTXF) 0.8900 $EDTXF Spec
Post# of 273242
Posted On: 09/14/2016 3:11:55 PM
Spectral Diagnostics (EDTXF) 0.8900 $EDTXF
Spectral Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Marketwire Canada - Wed Sep 07, 7:02AM CDT
TORONTO, ONTARIO--(Marketwired - Sep 7, 2016) - Spectral Medical Inc. ("Spectral" or the "Company"
(TSX:EDT)(OTCQX:EDTXF) a Phase III Company advancing a precision treatment targeting specific patients at high risk of death from endotoxemic septic shock, today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.
EDT.TO: 1.18 (+0.02)
Spectral Unaware of Any Material Change
Marketwire Canada - Fri Aug 19, 7:01AM CDT
Company Remains on Track With FDA Process and Timelines
EDT.TO: 1.18 (+0.02)
Spectral on Track With Regulatory Pathway for Novel Septic Shock Treatment
Marketwire Canada - Thu Aug 18, 7:01AM CDT
- Pivotal trial results to be announced immediately after end of Q3 16
EDT.TO: 1.18 (+0.02)
Spectral Announces Second Quarter Results
Marketwired - Fri Aug 12, 7:01AM CDT
TORONTO, ONTARIO--(Marketwired - Aug 12, 2016) - Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the second quarter ended June 30, 2016.
EDT.TO: 1.18 (+0.02)
Spectral Medical Announces Completion of Enrolment for Its Pivotal EUPHRATES Clinical Trial
Marketwired - Mon Jun 20, 7:02AM CDT
Company expects to announce primary clinical outcome results by end of September
EDT.TO: 1.18 (+0.02)
Spectral Medical Announces Acceptance of Pre-Clinical PMA Module for Toraymyxin(TM) by FDA
Marketwired - Thu Jun 16, 7:02AM CDT
Company remains on track and anticipates final submission in Q4 2016
EDT.TO: 1.18 (+0.02)
Spectral Announces Voting Results of Annual Meeting
Marketwire Canada - Wed Jun 01, 9:12AM CDT
TORONTO, ONTARIO--(Marketwired - Jun 1, 2016) - Spectral Medical Inc. ("Spectral" or the "Company" (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that at the annual meeting (the "Meeting" of shareholders of the Corporation ("Shareholders" that was held yesterday, all six nominees for the board were elected, the voting results of which are as follows:
EDT.TO: 1.18 (+0.02)
Spectral Medical Files Expanded Access Protocol With FDA for Toraymyxin(TM) Septic Shock Treatment
Marketwired - Tue May 31, 7:01AM CDT
Four patients remaining to enroll in the EUPHRATES clinical trial
EDT.TO: 1.18 (+0.02)
Spectral Announces First Quarter Results
Marketwired - Thu May 12, 7:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 12, 2016) - Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the first quarter ended March 31, 2016.
EDT.TO: 1.18 (+0.02)
Spectral Medical Provides Clinical and Regulatory Update
Marketwired - Mon Jan 11, 8:41AM CST
Spectral Medical Inc., ("Spectral" or the "Company" (TSX: EDT)(OTCQX: EDTXF), a Phase III company developing the first treatment for patients with endotoxemic septic shock that comprises a therapeutic device guided by a companion diagnostic, today announced that it is now recruiting the last 46 patients into its pivotal Phase III EUPHRATES trial. Based on current enrolment rates, it is expected that the trial should be completed in the first half of 2016.
EDT.TO: 1.18 (+0.02)
Spectral Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Marketwire Canada - Wed Sep 07, 7:02AM CDT
TORONTO, ONTARIO--(Marketwired - Sep 7, 2016) - Spectral Medical Inc. ("Spectral" or the "Company"
(TSX:EDT)(OTCQX:EDTXF) a Phase III Company advancing a precision treatment targeting specific patients at high risk of death from endotoxemic septic shock, today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City. EDT.TO: 1.18 (+0.02)
Spectral Unaware of Any Material Change
Marketwire Canada - Fri Aug 19, 7:01AM CDT
Company Remains on Track With FDA Process and Timelines
EDT.TO: 1.18 (+0.02)
Spectral on Track With Regulatory Pathway for Novel Septic Shock Treatment
Marketwire Canada - Thu Aug 18, 7:01AM CDT
- Pivotal trial results to be announced immediately after end of Q3 16
EDT.TO: 1.18 (+0.02)
Spectral Announces Second Quarter Results
Marketwired - Fri Aug 12, 7:01AM CDT
TORONTO, ONTARIO--(Marketwired - Aug 12, 2016) - Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the second quarter ended June 30, 2016.
EDT.TO: 1.18 (+0.02)
Spectral Medical Announces Completion of Enrolment for Its Pivotal EUPHRATES Clinical Trial
Marketwired - Mon Jun 20, 7:02AM CDT
Company expects to announce primary clinical outcome results by end of September
EDT.TO: 1.18 (+0.02)
Spectral Medical Announces Acceptance of Pre-Clinical PMA Module for Toraymyxin(TM) by FDA
Marketwired - Thu Jun 16, 7:02AM CDT
Company remains on track and anticipates final submission in Q4 2016
EDT.TO: 1.18 (+0.02)
Spectral Announces Voting Results of Annual Meeting
Marketwire Canada - Wed Jun 01, 9:12AM CDT
TORONTO, ONTARIO--(Marketwired - Jun 1, 2016) - Spectral Medical Inc. ("Spectral" or the "Company"
(TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that at the annual meeting (the "Meeting" of shareholders of the Corporation ("Shareholders" that was held yesterday, all six nominees for the board were elected, the voting results of which are as follows: EDT.TO: 1.18 (+0.02)
Spectral Medical Files Expanded Access Protocol With FDA for Toraymyxin(TM) Septic Shock Treatment
Marketwired - Tue May 31, 7:01AM CDT
Four patients remaining to enroll in the EUPHRATES clinical trial
EDT.TO: 1.18 (+0.02)
Spectral Announces First Quarter Results
Marketwired - Thu May 12, 7:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 12, 2016) - Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the first quarter ended March 31, 2016.
EDT.TO: 1.18 (+0.02)
Spectral Medical Provides Clinical and Regulatory Update
Marketwired - Mon Jan 11, 8:41AM CST
Spectral Medical Inc., ("Spectral" or the "Company"
(TSX: EDT)(OTCQX: EDTXF), a Phase III company developing the first treatment for patients with endotoxemic septic shock that comprises a therapeutic device guided by a companion diagnostic, today announced that it is now recruiting the last 46 patients into its pivotal Phase III EUPHRATES trial. Based on current enrolment rates, it is expected that the trial should be completed in the first half of 2016. EDT.TO: 1.18 (+0.02)
(0)
(0)Scroll down for more posts ▼